Vir Biotechnology Inc. (VIR)
NASDAQ: VIR
· Real-Time Price · USD
4.34
-0.14 (-3.13%)
At close: Aug 19, 2025, 11:52 AM
-3.13% (1D)
| Bid | 4.33 |
| Market Cap | 602.73M |
| Revenue (ttm) | 16.67M |
| Net Income (ttm) | -550.23M |
| EPS (ttm) | -4.01 |
| PE Ratio (ttm) | -1.08 |
| Forward PE | -1.43 |
| Analyst | Buy |
| Ask | 4.34 |
| Volume | 261,017 |
| Avg. Volume (20D) | 1,239,570.9 |
| Open | 4.48 |
| Previous Close | 4.48 |
| Day's Range | 4.30 - 4.48 |
| 52-Week Range | 4.16 - 14.45 |
| Beta | 1.18 |
Analyst Forecast
According to 0 analyst ratings, the average rating for VIR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Vir Biotechnology Inc. is scheduled to release its earnings on
Oct 30, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-0.59%
Vir Biotechnology shares are trading lower after t...
Unlock content with
Pro Subscription
7 months ago
+58.17%
Vir Biotechnology shares are trading higher after the company announced it's presenting initial Phase 1 data from its two dual-masked T-cell engagers (TCEs): VIR-5818 and VIR-5500.
3 weeks ago · seekingalpha.com
Vir Biotechnology: Hep B And Cancer Projects March OnVir Biotechnology: Hep B And Cancer Projects March On
